← Back to Skills Marketplace
hanxueyuan

Crispr Therapeutics

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0
cross-platform ✓ Security Clean
36
Downloads
0
Stars
0
Active Installs
1
Versions
Install in OpenClaw
/install crispr-therapeutics
Description
CRISPR Therapeutics develops CRISPR-Cas9 gene editing therapies, including FDA-approved Casgevy for sickle cell disease, partnering with Vertex Pharmaceuticals.
README (SKILL.md)

CRISPR Therapeutics

发展历程

  • 2013: Emmanuelle Charpentier和Emmanuelle de Silva在瑞士创立
  • 2015: 与Vertex Pharmaceuticals建立战略合作
  • 2016: 10月在纳斯达克上市
  • 2018: 启动CTX001(镰状细胞病)临床试验
  • 2019: CTX001数据显示治愈率近100%
  • 2020: Charpentier获诺贝尔化学奖(CRISPR基因编辑)
  • 2023: Casgevy获FDA批准,成为全球首个CRISPR基因编辑疗法
  • 2024: 与Vertex扩大合作,推进肿瘤学和自身免疫疾病管线

核心业务

CRISPR基因编辑疗法开发 + 与大型药企(如Vertex)的合作授权收入 + 内部管线推进

竞争优势

CRISPR-Cas9核心专利组合(与Broad Institute交叉授权)、首个获批疗法的临床验证、与Vertex的深度绑定、创始团队的诺贝尔奖声誉

关键指标

Casgevy定价$220万美元/疗程;与Vertex合作获得超$10亿里程碑付款;2024年市值约$50亿

故事

Casgevy是医学史上第一个使用CRISPR'基因剪刀'技术获批的疗法——它从患者体内取出造血干细胞,用CRISPR精确编辑后重新注入患者体内,从根本上治愈了镰状细胞病。治疗只需一次,但定价高达220万美元

Usage Guidance
This skill appears safe from a security perspective because it is an instruction-only informational reference. Users should still independently verify biomedical and investment-related facts before relying on them for medical, financial, or business decisions.
Capability Analysis
Type: OpenClaw Skill Name: crispr-therapeutics Version: 1.0.0 The skill bundle contains purely informational content regarding CRISPR Therapeutics, including its history, business model, and clinical milestones. There is no executable code, network activity, or malicious instructions within SKILL.md or _meta.json.
Capability Assessment
Purpose & Capability
The artifact is coherent with the stated purpose: it provides background information about CRISPR Therapeutics, its therapies, partnerships, and market context.
Instruction Scope
The skill contains reference content and read_when triggers only; it does not instruct the agent to override user intent, run tools, access accounts, or take actions.
Install Mechanism
There is no install specification, no code, no dependencies, and no required binaries.
Credentials
No environment variables, credentials, files, network access, or local system capabilities are requested.
Persistence & Privilege
The artifacts show no persistence, background execution, privileged access, memory use, or account authority.
How to Use
  1. Make sure OpenClaw is installed (local or Docker)
  2. Run the install command in chat: /install crispr-therapeutics
  3. After installation, invoke the skill by name or use /crispr-therapeutics
  4. Provide required inputs per the skill's parameter spec and get structured output
Version History
v1.0.0
- First public release of the CRISPR Therapeutics skill - Provides company background, major milestones, and business overview - Highlights CRISPR-Cas9's clinical and regulatory achievements, including the 2023 FDA approval of Casgevy - Covers competitive advantages, financial metrics, and collaboration details - Useful for understanding the commercialization and market impact of CRISPR gene editing therapies
Metadata
Slug crispr-therapeutics
Version 1.0.0
License MIT-0
All-time Installs 0
Active Installs 0
Total Versions 1
Frequently Asked Questions

What is Crispr Therapeutics?

CRISPR Therapeutics develops CRISPR-Cas9 gene editing therapies, including FDA-approved Casgevy for sickle cell disease, partnering with Vertex Pharmaceuticals. It is an AI Agent Skill for Claude Code / OpenClaw, with 36 downloads so far.

How do I install Crispr Therapeutics?

Run "/install crispr-therapeutics" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Crispr Therapeutics free?

Yes, Crispr Therapeutics is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Crispr Therapeutics support?

Crispr Therapeutics is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Crispr Therapeutics?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

💬 Comments